CoChat

Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways

Open access
Halani, Sameer H., Yousefi, Safoora, Velazquez Vega, Jose, Rossi, Michael R., Zhao, Zheng, Amrollahi, Fatemeh, Holder, Chad A., Baxter-Stoltzfus, Amelia, Eschbacher, Jennifer, Griffith, Brent, Olson, Jeffrey J., Jiang, Tao, Yates, Joseph R., Eberhart, Charles G., Poisson, Laila M., Cooper, Lee A. D., Brat, Daniel J. · 2018 · npj Precision Oncology
Cited by 50

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Oligodendrogliomas are diffusely infiltrative gliomas defined by IDH-mutation and co-deletion of 1p/19q. They have highly variable clinical courses, with survivals ranging from 6 months to over 20 years, but little is known regarding the pathways involved with their progression or optimal markers for stratifying risk. We utilized machine-learning approaches with genomic data from The Cancer Genome Atlas to objectively identify molecular factors associated with clinical outcomes of oligodendroglioma and extended these findings to study signaling pathways implicated in oncogenesis and clinical endpoints associated with glioma progression. Our multi-faceted computational approach uncovered key genetic alterations associated with disease progression and shorter survival in oligodendroglioma and specifically identified Notch pathway inactivation and PI3K pathway activation as the most strongly associated with MRI and pathology findings of advanced disease and poor clinical outcome. Our findings that Notch pathway inactivation and PI3K pathway activation are associated with advanced disease and survival risk will pave the way for clinically relevant markers of disease progression and therapeutic targets to improve clinical outcomes. Furthermore, our approach demonstrates the strength of machine learning and computational methods for identifying genetic events critical to disease progression in the era of big data and precision medicine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41698-018-0067-9

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 50

Metadata

Authors
Halani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., Olson, J. J., Jiang, T., Yates, J. R., Eberhart, C. G., Poisson, L. M., Cooper, L. A. D., & Brat, D. J.
Venue
npj Precision Oncology
Published
2018-11-06
Volume
2
Issue
1
Pages
24-24
ISSN
2397-768X (ISSN-L)
OpenAlex
W2896684230
Cited by
50
References
7
FWCI
2.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. https://app.cochat.ai/papers/10.1038/s41698-018-0067-9
The paper
Halani, S. H., Yousefi, S., Velazquez Vega, J., Rossi, M. R., Zhao, Z., Amrollahi, F., Holder, C. A., Baxter-Stoltzfus, A., Eschbacher, J., Griffith, B., Olson, J. J., Jiang, T., Yates, J. R., Eberhart, C. G., Poisson, L. M., Cooper, L. A. D., & Brat, D. J. (2018). Multi-faceted computational assessment of risk and progression in oligodendroglioma implicates NOTCH and PI3K pathways. npj Precision Oncology. https://doi.org/10.1038/s41698-018-0067-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.